DGAP-News: MorphoSys AG / Key word(s): Conference/Study results Planegg/Munich, Germany, November 2, 2017 MorphoSys Announces Presentation of Clinical Data on Proprietary Blood Cancer Compound MOR208 at Upcoming American Society of Hematology Annual Meeting 2017
- Abstract on preliminary data from ongoing phase 2 trial with antibody MOR208 in combination with lenalidomide in relapsed/refractory DLBCL accepted for poster presentation at ASH 2017 - Poster presentation will take place on December 11, 2017, 6:00-8:00pm EST (December 12, 0:00-2:00am CET) - Conference call by MorphoSys scheduled for December 12, 2017, 11:00am EST (5:00pm CET) MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX, OTC: MPSYY) today announced the upcoming presentation of data on the Company's proprietary investigational hemato-oncological program MOR208 at the 59th American Society of Hematology (ASH) Annual Meeting, being held December 9-12, 2017 in Atlanta, Georgia/USA. "We are pleased that updated clinical trial results of the phase 2 L-MIND study with our antibody MOR208 in combination with lenalidomide in patients with relapsed or refractory diffuse large B cell lymphoma (R/R DLBCL) who are not eligible for high-dose chemotherapy and autologous stem-cell transplantation will be shown at the upcoming ASH conference in a poster presentation," commented Dr. Malte Peters, Chief Development Officer of MorphoSys AG. "We see a particularly high unmet medical need for these blood cancer patients and look forward to presenting an update from our ongoing study in this patient group." Based on preliminary data from the L-MIND study presented in June 2017, the FDA had recently granted Breakthrough Therapy designation for MOR208, in combination with lenalidomide, for the treatment of patients with R/R DLBCL who are not eligible for high-dose chemotherapy and autologous stem-cell transplantation. Details about the abstract from MorphoSys's proprietary program MOR208 accepted for presentation at ASH 2017: The poster presentation will include updated clinical results, in particular with respect to safety and efficacy, from our phase 2 study L-MIND with MOR208 in combination with lenalidomide in adult patients with relapsed/refractory DLBCL who are not eligible for high-dose chemotherapy and autologous stem-cell transplantation. Abstract #4123; Poster III The poster will be presented during the Session #626 "Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Prospective Clinical Trials" on Monday, December 11, 2017, 6:00pm-8:00pm EST (Dec. 12, 2017, 0:00am-2:00am CET), in the Georgia World Congress Center, Bldg A, Lvl 1, Hall A2. In addition to the presentation, the abstract will be published online in the December 8, 2017 supplemental volume of Blood. Additional information can be found at www.hematology.org, including the abstract.
Dial-in details will be made available in time. The presentation, a live webcast and a replay of the webcast will be made available at http://www.morphosys.com. About MorphoSys: HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the MorphoSys Group. This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned. For more information, please contact: MorphoSys AG Jochen Orlowski Alexandra Goller Tel: +49 (0) 89 / 899 27-404 Additional features: Document: http://n.eqs.com/c/fncls.ssp?u=UKGGOMKSHY Document title: Media Release 02.11.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | MorphoSys AG |
Semmelweisstr. 7 | |
82152 Planegg | |
Germany | |
Phone: | +49 (0)89 899 27-0 |
Fax: | +49 (0)89 899 27-222 |
E-mail: | investors@morphosys.com |
Internet: | www.morphosys.com |
ISIN: | DE0006632003 |
WKN: | 663200 |
Indices: | TecDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
End of News | DGAP News Service |